ArticleBMC nephrology2026
A case of ADTKD-UMOD presenting with focal segmental glomerulosclerosis in a young male with a positive family history.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal segmental glomerulosclerosis (FSGS) is a pathological lesion with diverse etiologies. UMOD gene variants, typically associated with autosomal dominant tubulointerstitial kidney disease (ADTKD), are rarely reported as a cause of FSGS and remain poorly characterized. We report a young male patient with familial nephropathy whose renal biopsy revealed FSGS and whole-exome sequencing identified a heterozygous UMOD variant (OMIM: 191845), c.113 A > T (p.Asn38Ile). This case indicates that UMOD variants can manifest with FSGS as the predominant histological finding, and the accumulation of mutant uromodulin may initiate tubular injury and ultimately leading to secondary glomerulosclerosis. These findings highlight the necessity of incorporating genetic testing into FSGS evaluation to achieve precise diagnosis and guide management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.